Patients who have had at least 1 prior therapy or carry a 17p deletion or TP53 mutation are now eligible to be treated with ibrutinib (Imbruvica) in the United Kingdom.
Patients who have had at least 1 prior therapy or carry a 17p deletion or TP53 mutation are now eligible to be treated with the Burton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) developed by Janssen, according to the National Institutes of Health and Care Excellence (NICE), which is the agency that monitors funding for healthcare in England and Wales.
In early 2016, Janssen UK received news that NICE had rejected funding for ibrutinib, which was, at the time, being funded through UK’s Cancer Drug Fund. NICE had doubts about whether the drug—which cost £55,954.50 for a year’s course—would be cost effective. Mark Hicken, managing director of Janssen UK, had said then that the company was negotiating with NICE to demonstrate cost effectiveness and to ensure patient’s continued to have access to the drug.
Results from the RESONATE-2 trial could have swayed the decision in favor of the drug. At the 2016 annual meeting of the American Society of Hematology, Paul Barr, MD, assistant professor of medicine at the University of Rochester Wilmot Cancer Institute, reported impressive results from the trial. In a population of older treatment-naïve patients, the 24-month overall survival was 95% in the ibrutinib arm, compared with 84% for the comparator arm. Hematological functions, too, were significantly improved in patients treated with ibrutinib.
The company is now waiting to see whether NICE also clears ibrutinib for treating patients with mantle cell lymphoma and Waldenström's macroglobulinemia.
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More
7-Day Dosing of Azacytidine Shows Benefit for Females With High-Risk MDS Not Seen in Males
November 30th 2023Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men.
Read More